Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical AB's gross profit for the
three
months ended in Jun. 2026 was €-0.30 Mil. Spago Nanomedical AB's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.12 Mil.
Spago Nanomedical AB (FRA:7UX) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Spago Nanomedical AB had a gross margin of % for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Spago Nanomedical AB Gross Profit Related Terms
Spago Nanomedical AB Gross Profit Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7UX vs VRTX, REGN, MRNA: Gross Profit Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.12 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Spago Nanomedical AB (FRA:7UX) has a Gross Profit of €-1.12 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Gross Profit too high?
Spago Nanomedical AB's current Gross Profit is €-1.12 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Gross Profit compare to VRTX and REGN?
Spago Nanomedical AB's Gross Profit of €-1.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Gross Profit is €-1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current Gross Profit of €-1.12 Mil. The current Gross Profit is €-1.12 Mil. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current Gross Profit is €-1.12 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score
Get the complete analysis for FRA:7UX
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UX has been successfully added to your 
